What's Going On With Reneo Pharmaceuticals Stock Today?
What's Going On With Reneo Pharmaceuticals Stock Today?
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares initially traded higher Monday before turning negative after the company announced a proposed merger with OnKure, Inc.
Reneo Pharmicals, Inc.（纳斯达克股票代码：RPHM）的股价最初在周一上涨，然后在该公司宣布拟议与OnKure, Inc.进行合并后转为负值。
The Details: Reneo and Onkure announced Monday that they have entered into a definitive merger agreement to combine the two companies in an all-stock transaction.
详情：Reneo和Onkure周一宣布，他们已签订最终合并协议，将两家公司合并为全股交易。
The resulting company, expected to operate as OnKure Therapeutics, will focus on advancing OnKure's products targeting oncogenic mutations in phosphoinositide 3-kinase alpha. This includes OnKure's lead program OKI-219.
由此产生的公司预计将以OnKure Therapeutics的名义运营，将专注于推进OnKure针对磷酸肌苷3激酶α致癌突变的产品。这包括 OnKure 的主导项目 OKI-219。
"OnKure has an experienced team of drug developers, and we are excited about the potential for OKI-219 to become a meaningful treatment option for patients suffering from breast cancer," said Mike Grey, executive chairman of Reneo Pharmaceuticals.
Reneo Pharmicals执行董事长迈克·格雷表示：“OnKure拥有一支经验丰富的药物开发团队，我们对OKI-219 有可能成为乳腺癌患者有意义的治疗选择感到兴奋。”
In connection with the agreement, Reneo Pharmaceutics has entered into a subscription agreement for $65 million in private investment in public equity (PIPE) with a group of institutional investors, including Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital and Vestal Point Capital.
根据该协议，Reneo Pharmaceutics已与包括Acorn Bioventures、Cormorant Asset Management、Deep Track Capital、Perceptive Advisors、Samsara BioCapital、Surveyor Capital和Vestal Point Capital在内的一批机构投资者签订了6500万美元的公募股权私人投资（PIPE）的认购协议。
Including PIPE proceeds, the combined company is expected to hold about $120 million of cash, cash equivalents and short terms investments at closing.
包括PIPE收益在内，合并后的公司预计将在收盘时持有约1.2亿美元的现金、现金等价物和短期投资。
Pre-merger Reneo stockholders are anticipated to hold about 31% of the combined company's shares, while pre-merger OnKure stockholders are expected to own approximately 69%.
合并前的Reneo股东预计将持有合并后公司约31％的股份，而合并前的OnKure股东预计将拥有约69％的股份。
The merger and PIPE agreement are subject to approval by stockholders of both companies, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission and the condition that Reneo Pharmaceuticals has at least $55 million in net cash excluding the PIPE agreement. The transactions are expected to close later this year.
合并和PIPE协议须经两家公司股东的批准，向美国证券交易委员会提交的注册声明的有效性，以及不包括PIPE协议在内的Reneo Pharmicals拥有至少5500万美元的净现金的条件。这些交易预计将于今年晚些时候完成。
Related Link: Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
相关链接：本月可能挽救您的投资组合的四大医疗保健股票
RPHM Price Action: Reneo Pharmaceuticals shares were down 10.8% at $1.61 at the time of writing, according to Benzinga Pro.
RPHM价格走势：根据Benzinga Pro的数据，在撰写本文时，Reneo Pharmicals的股价下跌了10.8％，至1.61美元。
Image: 385506 from Pixabay.
图片：来自 Pixabay 的 385506。